Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

Test Type: 90-DAY

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH **AVERAGE SEVERITY GRADES[b]**

Sodium thioglycolate

CAS Number: 367-51-1

Time Report Reqsted: 10:56:49 First Dose M/F: 12/19/02 / 12/20/02

Date Report Regsted: 03/28/2008

Lab: MBA

C Number: C98007

Lock Date: 12/18/2003

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Include ALL **Treatment Groups:**

TDMSE Version: 1.9.1

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

Test Type: 90-DAY

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Sodium thioglycolate **CAS Number:** 367-51-1

Time Report Reqsted: 10:56:49 First Dose M/F: 12/19/02 / 12/20/02

Date Report Reqsted: 03/28/2008

Lab: MBA

B6C3F1 MICE MALE	VEHICLE CONTROL	22.5 MG/KG	45.0 MG/KG	90.0 MG/KG	180.0 MG/KG	360.0 MG/KG
Disposition Summary						
Animals Initially in Study Early Deaths Survivors	10	10	10	10	10	10
Terminal Sacrifice Animals Examined Microscopically	10 10	10 10	10 10	10 10	10 10	10 10
ALIMENTARY SYSTEM						
Liver Inflammation, Chronic Active	(10) 1 [1.0]	(0)	(0)	(0)	(0)	(10)
CARDIOVASCULAR SYSTEM						
None						
ENDOCRINE SYSTEM						
Adrenal Cortex Subcapsular, Hyperplasia Thyroid Gland Ectopic Thymus	(10) 2 [1.0] (9)	(0) (0)	(0)	(0)	(O) (O)	(10) 3 [1.0] (9) 1 [1.0]
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
None						
HEMATOPOIETIC SYSTEM						
Spleen	(10)	(0)	(0)	(0)	(0)	(10)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

Test Type: 90-DAY

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Sodium thioglycolate **CAS Number:** 367-51-1

Date Report Reqsted: 03/28/2008

Time Report Reqsted: 10:56:49 First Dose M/F: 12/19/02 / 12/20/02

Lab: MBA

B6C3F1 MICE MALE	VEHICLE CONTROL	22.5 MG/KG	45.0 MG/KG	90.0 MG/KG	180.0 MG/KG	360.0 MG/KG
Hematopoietic Cell Proliferation Thymus Thymocyte, Atrophy	10 [1.0] (7) 1 [1.0]	(0)	(0)	(0)	(0)	10 [1.0] (10)
INTEGUMENTARY SYSTEM						
Skin Sebaceous Gland, Site Of Application - Dermis, Hypertrophy	(10)	(10)	(10)	(10)	(10) 2 [1.0]	(10) 4 [1.0]
Site Of Application - Épidermis, Hyperkeratosis					3 [1.0]	3 [1.0]
Site Of Application - Epidermis,			1 [1.0]		2 [1.0]	1 [1.0]
Hyperplasia, Focal Site Of Application - Epidermis, Hyperplasia, Diffuse					3 [1.0]	6 [2.2]
MUSCULOSKELETAL SYSTEM						
None						
NERVOUS SYSTEM						
None						
RESPIRATORY SYSTEM						
None						
SPECIAL SENSES SYSTEM						
None						
URINARY SYSTEM						
Kidney Renal Tubule, Regeneration	(10)	(0)	(0)	(0)	(0)	(10) 2 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

Test Type: 90-DAY

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Sodium thioglycolate

CAS Number: 367-51-1

Date Report Reqsted: 03/28/2008

Time Report Reqsted: 10:56:49
First Dose M/F: 12/19/02 / 12/20/02

Lab: MBA

B6C3F1 MICE MALE	VEHICLE	22.5 MG/KG	45.0 MG/KG	90.0 MG/KG	180.0 MG/KG	360.0 MG/KG
	CONTROL					

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

Test Type: 90-DAY

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Sodium thioglycolate **CAS Number:** 367-51-1

Date Report Reqsted: 03/28/2008

Time Report Reqsted: 10:56:49

First Dose M/F: 12/19/02 / 12/20/02

Lab: MBA

B6C3F1 MICE FEMALE	VEHICLE CONTROL	22.5 MG/KG	45.0 MG/KG	90.0 MG/KG	180.0 MG/KG	360.0 MG/KG
Disposition Summary						
Animals Initially in Study Early Deaths Survivors	10	10	10	10	10	10
Terminal Sacrifice Animals Examined Microscopically	10 10	10 10	10 10	10 10	10 10	10 10
ALIMENTARY SYSTEM						
Liver Inflammation, Chronic Active Necrosis, Focal	(10) 2 [1.0]	(0)	(0)	(0)	(0)	(10) 5 [1.2] 3 [1.0]
CARDIOVASCULAR SYSTEM						
None						
ENDOCRINE SYSTEM						
Adrenal Cortex Subcapsular, Hyperplasia	(10) 10 [1.0]	(0)	(0)	(0)	(0)	(10) 10 [1.0]
Thyroid Gland Ectopic Thymus	(10)	(0)	(0)	(0)	(0)	(10) 1 [1.0]
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
Oviduct	(1) 1	(0)	(0)	(0)	(0)	(0)
Cyst Uterus Endometrium, Hyperplasia, Cystic	(10) 4 [1.0]	(0)	(0)	(0)	(0)	(10) 4 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

Test Type: 90-DAY

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Sodium thioglycolate **CAS Number:** 367-51-1

Date Report Reqsted: 03/28/2008

Time Report Reqsted: 10:56:49 First Dose M/F: 12/19/02 / 12/20/02

Lab: MBA

B6C3F1 MICE FEMALE	VEHICLE CONTROL	22.5 MG/KG	45.0 MG/KG	90.0 MG/KG	180.0 MG/KG	360.0 MG/K
HEMATOPOIETIC SYSTEM						
Spleen	(10)	(0)	(0)	(0)	(0)	(10)
Hematopoietic Cell Proliferation Thymus Thymocyte, Atrophy	8 [1.0] (10)	(0)	(0)	(0)	(0)	10 [1.0] (10) 1 [1.0]
NTEGUMENTARY SYSTEM						
Skin Sebaceous Gland, Site Of Application - Dermis, Hypertrophy	(10)	(10)	(10)	(10)	(10) 6 [1.0]	(10) 7 [1.0]
Site Of Application - Dermis,		1 [1.0]				
Hemorrhage, Focal Site Of Application - Dermis,		1 [2.0]		1 [1.0]		
Inflammation, Focal, Chronic Active Site Of Application - Dermis, Inflammation, Chronic Active					1 [1.0]	
Site Of Application - Epidermis, Exudate Site Of Application - Epidermis, Exudate, Focal		1	1 [1.0]			
Site Of Application - Epidermis,				1 [1.0]	1 [1.0]	4 [1.3]
Hyperkeratosis Site Of Application - Epidermis, Hyperplasia, Focal		1 [3.0]	3 [1.0]	1 [1.0]	3 [1.0]	2 [1.0]
Site Of Application - Epidermis,					6 [1.5]	8 [1.5]
Hyperplasia, Diffuse Site Of Application - Epidermis, Inflammation, Focal, Chronic Active			1 [1.0]			
Site Of Application - Epidermis, Inflammation, Chronic Active						1 [1.0]

NERVOUS SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

Test Type: 90-DAY

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Sodium thioglycolate **CAS Number:** 367-51-1

Time Report Regsted: 10:56:49

First Dose M/F: 12/19/02 / 12/20/02

Date Report Regsted: 03/28/2008

Lab: MBA

B6C3F1 MICE FEMALE	VEHICLE CONTROL	22.5 MG/KG	45.0 MG/KG	90.0 MG/KG	180.0 MG/KG	360.0 MG/KG
Brain Cyst Epithelial Inclusion	(10) 1	(0)	(0)	(0)	(0)	(10)
RESPIRATORY SYSTEM						
None						
SPECIAL SENSES SYSTEM						
None						
URINARY SYSTEM						
Kidney Inflammation, Chronic Active Renal Tubule, Casts Protein Renal Tubule, Regeneration	(10)	(0)	(0)	(0)	(0)	(10) 1 [1.0] 1 [1.0] 1 [1.0]

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)